Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12508557 | 0.94 | MAPK1 (0.47) | FAAHALDH1A1KDM4EMAPK1TSHR | |
| SCHEMBL25120241 | 0.90 | MEN1 (0.46) | FAAHMAPK1HCRTR1HCRTR2 | |
| SCHEMBL12508835 | 0.89 | ALDH1A1 (0.51) | FAAHALDH1A1KDM4EMAPK1TSHR | |
| SCHEMBL12509364 | 0.82 | ABL1 (0.49) | FAAHALDH1A1KDM4EMAPK1TSHR | |
| SCHEMBL12509074 | 0.81 | EPHX2 (0.51) | FAAHALDH1A1MAPK1TSHR | |
| SCHEMBL12509209 | 0.81 | POLB (0.43) | FAAHALDH1A1KDM4EHCRTR1HCRTR2 | |
| SCHEMBL12509410 | 0.81 | ALDH1A1 (0.53) | FAAHALDH1A1 | |
| SCHEMBL12509399 | 0.80 | MGLL (0.51) | FAAHALDH1A1KDM4EMAPK1TSHR | |
| SCHEMBL25120242 | 0.80 | HCRTR1 (0.46) | FAAHALDH1A1KDM4EMAPK1CFTR | |
| SCHEMBL12508869 | 0.80 | MGLL (0.51) | FAAHALDH1A1KDM4EMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | FAAH 1/4885ALDH1A1 259/4885KDM4E 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.